{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:01:09Z","timestamp":1792598469011,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012550","name":"Nemzeti Kutat\u00e1si, Fejleszt\u00e9si \u00e9s Innovaci\u00f3s Alap","doi-asserted-by":"publisher","award":["\u00daNKP-21-4-I-SE"],"award-info":[{"award-number":["\u00daNKP-21-4-I-SE"]}],"id":[{"id":"10.13039\/501100012550","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["K24HL150238"],"award-info":[{"award-number":["K24HL150238"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL130539"],"award-info":[{"award-number":["R01HL130539"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL137562"],"award-info":[{"award-number":["R01HL137562"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["T32HL076136"],"award-info":[{"award-number":["T32HL076136"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015498","name":"Innov\u00e1ci\u00f3s \u00e9s Technol\u00f3giai Miniszt\u00e9rium","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015498","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["147814"],"award-info":[{"award-number":["147814"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.jchf.2022.03.006","type":"journal-article","created":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T14:10:54Z","timestamp":1654697454000},"page":"559-567","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":146,"title":["Sodium-Glucose Co-Transporter-2 Inhibitors and Cardiac Outcomes Among Patients Treated With Anthracyclines"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0383-2086","authenticated-orcid":false,"given":"Carlos A.","family":"Gongora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsofia D.","family":"Drobni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thiago","family":"Quinaglia Araujo Costa Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amna","family":"Zafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Zlotoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah K.","family":"Gilman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supraja","family":"Sama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Nikolaidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giselle Alexandra","family":"Suero-Abreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy S.","family":"Abramson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ephraim","family":"Hochberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Armand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paaladinesh","family":"Thavendiranathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7113-1118","authenticated-orcid":false,"given":"Anju","family":"Nohria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas G.","family":"Neilan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jchf.2022.03.006_bib1","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2174\/157340311799960645","article-title":"Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment","volume":"7","author":"Volkova","year":"2011","journal-title":"Curr Cardiol Rev"},{"issue":"12","key":"10.1016\/j.jchf.2022.03.006_bib2","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1056\/NEJMcibr1214975","article-title":"Anthracyclines and heart failure","volume":"368","author":"Sawyer","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.jchf.2022.03.006_bib3","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.amjcard.2012.11.022","article-title":"Myocardial extracellular volume by cardiac magnetic resonance imaging in patients treated with anthracycline-based chemotherapy","volume":"111","author":"Neilan","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jchf.2022.03.006_bib4","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.amjcard.2012.07.040","article-title":"Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines","volume":"110","author":"Neilan","year":"2012","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.jchf.2022.03.006_bib5","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1200\/OP.21.00075","article-title":"Cardiotoxicity monitoring in patients with cancer: focus on safety and clinical relevance","volume":"17","author":"Suero-Abreu","year":"2021","journal-title":"JCO Oncol Pract"},{"issue":"17","key":"10.1016\/j.jchf.2022.03.006_bib6","article-title":"Anthracycline cardiomyopathy","volume":"11","author":"Favreau-Lessard","year":"2018","journal-title":"Circ Heart Fail"},{"issue":"3","key":"10.1016\/j.jchf.2022.03.006_bib7","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1002\/j.2040-4603.2015.tb00641.x","article-title":"Anthracycline-induced cardiomyopathy in adults","volume":"5","author":"Tan","year":"2015","journal-title":"Compr Physiol"},{"issue":"9","key":"10.1016\/j.jchf.2022.03.006_bib8","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.jacc.2014.06.1167","article-title":"Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities","volume":"64","author":"Vejpongsa","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2022.03.006_bib9","first-page":"1","article-title":"Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series","volume":"5","author":"Ganatra","year":"2019","journal-title":"Cardiooncology"},{"issue":"12","key":"10.1016\/j.jchf.2022.03.006_bib10","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","article-title":"SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control","volume":"17","author":"Cowie","year":"2020","journal-title":"Nat Rev Cardiol"},{"issue":"21","key":"10.1016\/j.jchf.2022.03.006_bib11","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"10254","key":"10.1016\/j.jchf.2022.03.006_bib12","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jchf.2022.03.006_bib13","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12933-020-01040-5","article-title":"Empagliflozin prevents doxorubicin-induced myocardial dysfunction","volume":"19","author":"Sabatino","year":"2020","journal-title":"Cardiovasc Diabetol"},{"issue":"12","key":"10.1016\/j.jchf.2022.03.006_bib14","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.4070\/kcj.2019.0180","article-title":"Cardioprotective potential of an SGLT2 inhibitor against doxorubicin-induced heart failure","volume":"49","author":"Oh","year":"2019","journal-title":"Korean Circ J"},{"issue":"1","key":"10.1016\/j.jchf.2022.03.006_bib15","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1038\/s41598-018-19658-7","article-title":"Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH","volume":"8","author":"Shiba","year":"2018","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.jchf.2022.03.006_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-022577","article-title":"Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis","volume":"9","author":"Donnan","year":"2019","journal-title":"BMJ Open"},{"issue":"7","key":"10.1016\/j.jchf.2022.03.006_bib17","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004560","article-title":"Left ventricular mass change after anthracycline chemotherapy","volume":"11","author":"Jordan","year":"2018","journal-title":"Circ Heart Fail"},{"issue":"20","key":"10.1016\/j.jchf.2022.03.006_bib18","article-title":"SGLT-2 inhibitors in heart failure: current management, unmet needs, and therapeutic prospects","volume":"8","author":"Lam","year":"2019","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.jchf.2022.03.006_bib19","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1507\/endocrj.EJ19-0428","article-title":"SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation","volume":"67","author":"Komatsu","year":"2020","journal-title":"Endocr J"},{"issue":"4","key":"10.1016\/j.jchf.2022.03.006_bib20","doi-asserted-by":"crossref","first-page":"248","DOI":"10.7326\/M18-3136","article-title":"Sodium-glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections: a population-based cohort study","volume":"171","author":"Dave","year":"2019","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.jchf.2022.03.006_bib21","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.critrevonc.2004.11.003","article-title":"Incidence of febrile neutropenia and neutropenic infections in elderly patients receiving anthracycline-based chemotherapy for breast cancer without primary prophylaxis with colony-stimulating factors","volume":"53","author":"Minisini","year":"2005","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"10.1016\/j.jchf.2022.03.006_bib22","doi-asserted-by":"crossref","first-page":"837","DOI":"10.4103\/ijem.IJEM_159_17","article-title":"Genital infections with sodium glucose cotransporter-2 inhibitors: occurrence and management in patients with type 2 diabetes mellitus","volume":"22","author":"Unnikrishnan","year":"2018","journal-title":"Indian J Endocrinol Metab"},{"key":"10.1016\/j.jchf.2022.03.006_bib23","series-title":"R: A Language and Environment for Statistical Computing","year":"2019"},{"key":"10.1016\/j.jchf.2022.03.006_bib24","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.15420\/cfr.2020.23","article-title":"Sodium-glucose co-transporter 2 inhibitors in heart failure: recent data and implications for practice","volume":"6","author":"Rosano","year":"2020","journal-title":"Card Fail Rev"},{"issue":"10166","key":"10.1016\/j.jchf.2022.03.006_bib25","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"issue":"suppl 1","key":"10.1016\/j.jchf.2022.03.006_bib26","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.amjcard.2019.10.026","article-title":"Preventing and treating heart failure with sodium-glucose co-transporter 2 inhibitors","volume":"124","author":"Vaduganathan","year":"2019","journal-title":"Am J Cardiol"},{"issue":"7","key":"10.1016\/j.jchf.2022.03.006_bib27","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1007\/s00018-020-03729-y","article-title":"Molecular mechanisms of doxorubicin-induced cardiotoxicity: novel roles of sirtuin 1-mediated signaling pathways","volume":"78","author":"Wang","year":"2021","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"10.1016\/j.jchf.2022.03.006_bib28","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12933-021-01346-y","article-title":"The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin","volume":"20","author":"Quagliariello","year":"2021","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.jchf.2022.03.006_bib29","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12933-019-0980-4","article-title":"Sodium-glucose cotransporter 2 inhibitor dapagliflozin attenuates diabetic cardiomyopathy","volume":"19","author":"Arow","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jchf.2022.03.006_bib30","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.freeradbiomed.2018.08.032","article-title":"AMPK\/PGC1\u03b1 activation by melatonin attenuates acute doxorubicin cardiotoxicity via alleviating mitochondrial oxidative damage and apoptosis","volume":"129","author":"Liu","year":"2018","journal-title":"Free Radic Biol Med"},{"issue":"9","key":"10.1016\/j.jchf.2022.03.006_bib31","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.007197","article-title":"Cardioprotective effects of sirtuin-1 and its downstream effectors","volume":"13","author":"Packer","year":"2020","journal-title":"Circ Heart Fail"},{"issue":"8","key":"10.1016\/j.jchf.2022.03.006_bib32","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1111\/dom.13745","article-title":"Sodium-glucose co-transporter-2 (SGLT-2) inhibitors and cancer: a meta-analysis of randomized controlled trials","volume":"21","author":"Dicembrini","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"10.1016\/j.jchf.2022.03.006_bib33","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1007\/s00125-017-4370-8","article-title":"SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials","volume":"60","author":"Tang","year":"2017","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.jchf.2022.03.006_bib34","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1177\/1060028020951928","article-title":"Prevention and management of genital mycotic infections in the setting of sodium-glucose cotransporter 2 inhibitors","volume":"55","author":"Engelhardt","year":"2021","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jchf.2022.03.006_bib35","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40170-019-0203-1","article-title":"SGLT2 inhibition slows tumor growth in mice by reversing hyperinsulinemia","volume":"7","author":"Nasiri","year":"2019","journal-title":"Cancer Metab"},{"issue":"10","key":"10.1016\/j.jchf.2022.03.006_bib36","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.molmet.2016.08.014","article-title":"The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration","volume":"5","author":"Villani","year":"2016","journal-title":"Mol Metab"},{"issue":"467","key":"10.1016\/j.jchf.2022.03.006_bib37","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat5933","article-title":"Sodium-glucose transporter 2 is a diagnostic and\u00a0therapeutic target for early-stage lung adenocarcinoma","volume":"10","author":"Scafoglio","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jchf.2022.03.006_bib38","doi-asserted-by":"crossref","first-page":"110821","DOI":"10.1016\/j.biopha.2020.110821","article-title":"Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK\/mTOR pathway","volume":"132","author":"Zhou","year":"2020","journal-title":"Biomed Pharmacother"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177922002384?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177922002384?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:00:38Z","timestamp":1761973238000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177922002384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S2213177922002384"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2022.03.006","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sodium-Glucose Co-Transporter-2 Inhibitors and Cardiac Outcomes Among Patients Treated With Anthracyclines","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2022.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}